Eli Lilly’s new, $1B pain drug racks up another promising round of PhIII pain data
Eli Lilly spent close to a billion dollars to get its hands on the migraine drug lasmiditan, bagging CoLucid in January as a way to build its pain drug franchise. And it’s paying off today with another round of positive Phase III data as Lilly navigates it way to an expected regulatory filing next year.
Lilly hopes to differentiate this drug by focusing on the drug’s ability to deliver fast relief from severe pain. And while its new Phase III data is dogged by high placebo responses, researchers were able to nail down statistically significant improvements in response in the drug arms.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.